FDA Approves Novel Drug Enfortumab Vedotin for Urothelial Cancer
The US Food and Drug Administration has granted accelerated approval to the novel agent enfortumab vedotin (PADCEV, Astellas) for the treatment of locally advanced or metastatic urothelial cancer that has progressed on chemotherapy and immunotherapy.Source: Medscape
Backed by Yale Cancer Center Research, FDA Approves New Drug for Advanced Bladder Cancer
The U.S. Food and Drug Administration has granted accelerated approval to the drug enfortumab vedotin to treat adult patients with advanced urothelial or bladder cancer. The approval is the direct result of a multi-institutional clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers.
Daniel P. Petrylak, MD, regarding PD-L1 biomarkers in the treatment of bladder cancer
Dr. Petrylak, Professor of Medicine (Medical Oncology) and of Urology; Co-Director, Signal Transduction Research Program, Yale Cancer Center, considers whether PD-L1 biomarkers are useful in the treatment of bladder cancer.Source: OBR Oncology
Two-drug therapy for advanced UC shows superior PFS
Adding ramucirumab (CYRAMZA) to standard docetaxel (Taxotere) improved progression-free survival (PFS) compared with docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.Source: Urology Times
Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial
Daniel P. Petrylak, MD, of Yale Cancer Center, discusses phase III study findings on docetaxel with or without ramucirumab in platinum-refractory advanced or metastatic urothelial carcinoma.Source: Journal of the National Comprehensive Cancer Network (JNCNN 360)
Urothelial Carcinoma on Verge of Treatment Revolution
An upcoming FDA decision for the PD-L1 inhibitor atezolizumab as a treatment for patients with bladder cancer could set the stage for an onslaught of new and highly effective immuno-oncology agents, according to Daniel Petrylak, MD, at the New York GU™: 9th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary Malignancies.Source: Targeted Oncology
Addition of ramucirumab to docetaxel extends PFS in advanced urothelial cancer
The addition of ramucirumab to docetaxel conferred a small but statistically significant PFS benefit for patients with advanced or metastatic urothelial cancer whose disease progressed on platinum-based chemotherapy, according to results of a randomized phase 3 study presented at the European Society for Medical Oncology Annual Meeting. The numerical improvement in PFS equated to less than 2 months. However, a higher objective response rate in the experimental treatment group helps demonstrate the benefit ramucirumab (Cyramza, Eli Lilly) can have for this patient population, Daniel P. Petrylak, MD, professor of medicine and urology at Yale School of Medicine and Yale Cancer Center, told HemOnc Today.Source: Healio
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
The paper, ""Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer" was highlighted as a Feature Article for the November issue of Nanomedicine: NBM (Elsevier). Robert Weiss, MD, Darryl Martin, PhD, W. Mark Saltzman, PhD and more.